Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma-Reference-Cited by-同舟云学术

Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma

Published:2016-06-09 Issue:7 Volume:12 Page:813-822
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Calzetta Luigino¹,Rinaldi Barbara²,Cazzola Mario¹,Matera Maria Gabriella²

Affiliation:

1. Department of Systems Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome Tor Vergata, Roma, Italy

2. Department of Experimental Medicine, Section of Pharmacology ‘L. Donatelli’, Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2016.1192125

Reference68 articles.

1. Combination treatment in asthma: Reviewing old and new options

2. Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma

3. In Vitro/In VivoComparisons in Pulmonary Drug Delivery

4. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

5. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma;Expert Opinion on Drug Metabolism & Toxicology;2023-06-03

2. Cardiovascular disease in asthma patients: From mechanisms to therapeutic implications;Kardiologia Polska;2023-03-27

3. Metabolically Inactivated Glucocorticoids;SpringerBriefs in Molecular Science;2023

4. ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts;Advances in Respiratory Medicine;2022-09-29

5. Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD);Expert Opinion on Pharmacotherapy;2019-04-14